Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06151808
Other study ID # STB-XTR006-IIT-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date January 10, 2024

Study information

Verified date May 2024
Source Sinotau Pharmaceutical Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive impairment(MCI)due to AD and mild to moderate AD based on clinical diagnosis, and to establish XTR006 PET imaging parameters and qualitative reading and quantitative analysis methods.


Description:

XTR006 is a 18F-labeled PET tracer, for the quantification of neurofibrillary tangle (NFT) deposition in the brain. Brain NFT deposition is a pathologic finding in Alzheimer's Disease (AD), with brain NFT density shown to correlate with the severity of cognitive impairment in AD. 90 Chinese subjects (30 subjects with non-cognitive impairment, 30 subjects with MCI due to AD and 30 subjects with mild to moderate AD) who meet all of the inclusion and none of the exclusion criteriawill be enrolled in this IIT study. Subjects will receive 8-10mCi of XTR006 via IV injection. qualitative reading and quantitative analysis methods will be investigated. Safety and tolerability will be observed.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date January 10, 2024
Est. primary completion date November 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria: - 1. Inclusion criteria for non-cognitively impaired subjects 1. Male or female aged between 55 to 85 years old (including 50 and 85 years old); 2. Clinical dementia score (CDR) of 0; 3. the Mini-Mental State Examination Scale (MMSE score) of =28; 4. Aß PET imaging is negative; 5. Able to cooperate with the tests required for research including neuropsychological tests (cognitive ability, language ability, visual and auditory acuity can meet the requirements of the test); 6. The researcher judges that the subjects are in good health, and there is no abnormal or abnormality in the comprehensive physical examination, vital sign examination and laboratory examination, but they can participate in this bridging clinical trial according to the judgment of the clinician; 7. For women of potential fertility (not yet or within 2 years of menopause), effective contraceptive measures must be used during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, intrauterine hormonal devices, contraception condoms, contraceptives/dose, abstinence or partner removal of the vas deferens, etc.); male subjects should agree to use contraceptives during the study period and within 6 months after the end of the study period; 8. Able to sign the informed consent form. - 2. Inclusion criteria for MCI due to AD 1. Male or female aged between 55-85 years old (including 50 and 85 years old); 2. Diagnosed as MCI due to AD according to NIA-AA standard in 2011; 3. Have symptoms of subjective memory loss and maintain independent ability of daily life; 4. MMSE score=27; 5. CDR score=0.5; 6. Aß PET imaging is positive; 7. Able to cooperate with the tests required for research including neuropsychological tests (cognitive ability, language ability, visual and auditory acuity can meet the requirements of the test); 8. For women of potential fertility (not yet or within 2 years of menopause), effective contraceptive measures must be used during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, intrauterine hormonal devices, contraception condoms, contraceptives/dose, abstinence or partner removal of the vas deferens, etc.); male subjects should agree to use contraceptives during the study period and within 6 months after the end of the study period; 9. Able to sign the informed consent form. - 3. Inclusion criteria for subjects with mild to moderate AD 1. Male or female aged between 50-85 years old (including 55 and 85 years old); 2. Diagnosed as probable AD according to NIA-AA standard in 2011; 3. MMSE score=27 4. 1=CDR score=2; 5. Aß PET imaging is positive; 6. Have the ability to complete the cognitive ability test and other tests specified in the protocal; 7. The investigator judges that the subject's "caregiver" can provide accurate information and report on the patient's cognitive and functional abilities; 8. For women of potential fertility (not yet menopause or within 2 years of menopause), effective contraceptive measures must be used during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, intrauterine hormonal devices, contraception condoms, contraceptives/dose, abstinence or partner removal of the vas deferens, etc.); male subjects should agree to use contraceptives during the study period and within 6 months after the end of the study period; 9. Able to sign the informed consent form. Exclusion Criteria: - 1. Exclusion criteria for non-cognitively impaired subjects 1. years of education =6 years; 2. Severe neurological diseases, such as cerebrovascular diseases, inflammatory or infectious diseases, or any metabolic encephalopathy, neurodegenerative diseases, including Parkinson's disease history or physical or imaging manifestations; 3. History of severe craniocerebral injury, craniocerebral surgery or intracranial hematoma with permanent brain injury; 4. The results of cranial magnetic resonance imaging (MRI) also meet the following imaging findings: ?There are two or more infarcts outside the brain stem (diameter greater than 2 cm); ?Key parts such as thalamus, hippocampus, entorhinal cortex and angular gyrus Lacunar infarction; ?Fazekas score of high white matter damage =4; 5. Brain MRI examination showed enlarged perivascular space with subcortical diameter >3mm in short axis; 6. SWI (susceptibility-weighted imaging) prompts: cerebral microbleeds =8 locations; 7. History of alcohol or drug abuse/dependence; 8. Contraindications of MRI examination: such as heart pacemaker or nerve stimulator or metal foreign body, high fever, etc.; 9. Invasive surgery is planned within one week after administration of the study drug; 10. Allergy to the investigational drug or any of its components and/or a history of severe allergic reaction to the drug or allergens (such as history of alcohol allergy or allergic asthma); 11. Any major disease or unstable disease state (such as unstable angina pectoris, myocardial infarction or coronary revascularization, heart failure, acute and chronic renal failure, chronic liver disease, severe lung disease, blood disease, poor blood sugar control, chronic infection in the past 2 years, received surgical treatment 7 days ago, advanced cardiac insufficiency (New York Heart Association (NYHA stage IV), etc.); 12. History of tumor within 5 years (except cervical carcinoma in situ, prostate carcinoma in situ or local skin cancer after surgery); 13. Human immunodeficiency virus (HIV), hepatitis C or Treponema pallidum antibody test positive, hepatitis B surface antigen positive (except hepatitis B carriers); 14. Received drug therapy or other treatments (such as chemotherapy) that cause large fluctuations in hematological or biochemical indicators or serious side effects within two weeks before the screening examination; 15. Receive any contrast agent or radiopharmaceutical within 48 hours before application of test drug, or will use contrast agent within 24 hours after administration of study drug; 16. Participated in clinical research of other drugs within 30 days before enrollment or within 5 half-lives of the study drug (whichever is longer), and/or used any radiopharmaceuticals before the administration of the study drug, and not more than 10 radioactive half-lives apart; 17. History of epilepsy; 18. History of electroconvulsive therapy; 19. History of delirium (e.g. after surgery); 20. Other investigators deem it inappropriate to participate in the trial. - 2. Exclusion criteria for subjects with MCI due to AD and mild to moderate AD 1. years of education =6 years; 2. Epilepsy episode occurred within the past 1 year; 3. Dementia caused by other reasons or cognitive dysfunction caused by other reasons: such as vascular dementia, Parkinson's disease dementia, Lewy body dementia, normal intracranial pressure hydrocephalus, intracranial mass, central nervous system infection (Such as HIV, syphilis, etc.), metabolic encephalopathy, etc.; 4. The results of cranial MRI also meet the following imaging findings: ?There are more than two infarcts outside the brain stem (diameter greater than 2 cm); ?Lacunar infarction in key parts such as the thalamus, hippocampus, entorhinal cortex and angular gyrus ?The Fazekas score of high white matter damage = 4; 5. Brain MRI examination showed enlarged perivascular space with subcortical diameter >3mm in short axis; 6. SWI prompt: cerebral microbleeds =8 locations; 7. History of alcohol or drug abuse/dependence; 8. Contraindications of MRI examination: such as heart pacemaker or nerve stimulator or metal foreign body, high fever, etc.; 9. Subjects who plan to undergo surgery and/or other invasive surgery within 24 hours after the application of the trial drug; 10. Allergy to the investigational drug or any of its components and/or history of severe allergic reaction to the drug or allergens (such as history of alcohol allergy or allergic asthma); 11. Any major disease or unstable disease state (such as unstable angina pectoris, myocardial infarction or coronary revascularization, heart failure, acute and chronic renal failure, chronic liver disease, severe lung disease, blood Diabetic patients with disease, poor blood sugar control, chronic infection in the past 2 years, received surgical treatment 7 days ago, advanced cardiac insufficiency (NYHA stage IV), major depressive episode, etc.); 12. History of tumor within 5 years (except cervical carcinoma in situ, prostate carcinoma in situ or local skin cancer after surgery); 13. HIV, hepatitis C or Treponema pallidum antibody test positive, hepatitis B surface antigen positive (except hepatitis B carriers); 14. History of severe craniocerebral injury, craniocerebral surgery or intracranial hematoma with permanent brain injury; 15. Received drug therapy or other treatments (such as chemotherapy) that cause large fluctuations in hematological or biochemical indicators or serious side effects within two weeks before the screening examination; 16. Receive any contrast agent or radiopharmaceutical within 48 hours before application of test drug, or will use contrast agent within 24 hours after administration of test drug; 17. Participated in clinical research of other drugs within 30 days before enrollment or within 5 half-lives of the study drug (whichever is longer), and/or used any radiopharmaceuticals before the administration of the study drug, and not more than 10 radioactive half-lives apart; 18. Other investigators deem it inappropriate to participate in the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
XTR006
All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan

Locations

Country Name City State
China Chinese PLA General Hospital Beijing Beijing Shi

Sponsors (1)

Lead Sponsor Collaborator
Sinotau Pharmaceutical Group

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary To investigate the sensitivity and specificity of XTR006 PET imaging by reading Sensitivity and specificity of XTR006 PET images for diagnosis of MCI and AD will be measured by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis. day 1
Primary To investigate the sensitivity and specificity of XTR006 PET imaging by SUVR Sensitivity and specificity of XTR006 PET images for diagnosis of MCI and AD will be measured by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis. day 1
Secondary To investigate the parameters of XTR006 PET imaging in the brain PET images were collected 0-130min after a single intravenous administration of XTR006, and the start time when the SUVR value of Braak brain region was stable with cerebellar gray matter as the reference area was analyzed 0 to 130 minutes post injection
Secondary To investigate the methodology of XTR006 PET qualitative reading Sensitivity and specificity of different XTR006 PET qualitative reading rules for diagnosis of MCI and AD. day 1
Secondary To investigate the consistency among XTR006 PET readers and the reproducibility of the readers themselves. Kappa value between XTR006 PET images readers and Kappa value of readers themselves. day 1
Secondary To investigate the quantitative analysis methodology of XTR006 PET. SUVR cut off value and Sensitivity/specificity of different XTR006 PET quantitative analysis rules for diagnosis of MCI and AD. day 1
Secondary Descripte study product-related adverse events by numbers,degree and kinds as assessed by CTCAE v5.0 Safety Observation: Number of participants with adverse events and severe adverse events after drug injection. up to 7days
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A